Last $1,240 MXN
Change Today 0.00 / 0.00%
Volume 0.0
NVSN On Other Exchanges
Symbol
Exchange
SIX Swiss Ex
Xetra
New York
OTC US
Mexico
SIX Swiss Ex
Frankfurt
As of 4:09 PM 10/28/14 All times are local (Market data is delayed by at least 15 minutes).

novartis ag-sponsored adr (NVSN) Snapshot

Open
$1,240
Previous Close
$1,240
Day High
$1,240
Day Low
$1,240
52 Week High
10/1/14 - $1,255
52 Week Low
12/18/13 - $1,001
Market Cap
3.4T
Average Volume 10 Days
2.3K
EPS TTM
--
Shares Outstanding
2.7B
EX-Date
02/27/14
P/E TM
--
Dividend
$2.74
Dividend Yield
2.96%
Current Stock Chart for NOVARTIS AG-SPONSORED ADR (NVSN)

novartis ag-sponsored adr (NVSN) Related Businessweek News

View More BusinessWeek News

novartis ag-sponsored adr (NVSN) Details

Its Pharmaceuticals division offers patented prescription medicines in various therapeutic areas, including oncology; primary care and established medicines; specialty care, such as ophthalmology, neuroscience, integrated hospital care, and critical care; and cardiovascular and metabolism. The company’s Alcon division provides various eye care products, including ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses; medicines to treat chronic and acute diseases of the eye; over-the-counter medicines for the eye; and contact lenses and lens care products. Its Sandoz division offers prescription medicines, as well as pharmaceutical and biotechnological active substances. This division provides active ingredients and finished dosage forms of pharmaceuticals; active pharmaceutical ingredients and intermediates, primarily antibiotics; protein or biotechnology-based products; cytotoxic products for the hospital market; and biotech manufacturing services to other companies. The company’s Vaccines and Diagnostics division provides preventive human vaccines. Its Consumer Health division offers over-the-counter medicines comprising readily available consumer medicines; and Animal Health, which provides veterinary products for farm and companion animals. The company distributes its OTC products through various channels, such as food, drug, and mass retail outlets, as well as pharmacies; and Animal Health products directly and through wholesalers of veterinary products. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.

135,696 Employees
Last Reported Date: 01/29/14
Founded in 1895

novartis ag-sponsored adr (NVSN) Top Compensated Officers

Chief Executive Officer and Member of Executi...
Total Annual Compensation: SFr.3.1M
Chief Financial Officer and Member of Executi...
Total Annual Compensation: SFr.747.1K
President of Institutes for Biomedical Resear...
Total Annual Compensation: $1.9M
Division Head of Novartis Pharmaceuticals and...
Total Annual Compensation: $2.0M
Division Head of Animal Health and Member of ...
Total Annual Compensation: SFr.1.4M
Compensation as of Fiscal Year 2013.

novartis ag-sponsored adr (NVSN) Key Developments

Novartis AG Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Sales Guidance for the Full Year 2014

Novartis AG reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported net sales to third parties from continuing operations of USD 12,991 million against USD 12,705 million a year ago. Net sales of segments from continuing operations were USD 13,046 million against USD 12,574 million a year ago. Operating income from continuing operations were USD 2,739 million against USD 2,558 million a year ago. Income before taxes from continuing operations were USD 3,532 million against USD 2,488 million a year ago. Net income from continuing operations was USD 3,102 million or USD 1.25 per diluted share against USD 2,159 million or USD 0.86 per diluted share a year ago. Total net income attributable to shareholders of the company was USD 3,223 million or USD 1.31 per diluted share against USD 2,232 million or USD 0.90 per diluted share a year ago. Total cash flows from operating activities were USD 4,011 million against USD 4,379 million a year ago. Purchase of property, plant & equipment was USD 668 million against USD 759 million a year ago. For the nine months, the company reported net sales to third parties from continuing operations of USD 39,105 million against USD 38,480 million a year ago. Net sales of segments from continuing operations were USD 39,289 million against USD 38,650 million a year ago. Operating income from continuing operations were USD 8,738 million against USD 8,650 million a year ago. Income before taxes from continuing operations were USD 9,516 million against USD 8,524 million a year ago. Net income from continuing operations was USD 8,279 million or USD 3.32 per diluted share against USD 7,294 million or USD 2.90 per diluted share a year ago. Total net income attributable to shareholders of the company was USD 8,719 million or USD 3.52 per diluted share against USD 7,146 million or USD 2.88 per diluted share a year ago. Total cash flows from operating activities were USD 8,692 million against USD 8,724 million a year ago. Purchase of property, plant & equipment was USD 1,794 million against USD 1,855 million a year ago. As of September 30, 2014, the net debt stood at USD 9.2 billion compared to USD 8.8 billion at December 31, 2013. The company confirmed its outlook for the year 2014 of low to mid-single digit growth in net sales and core operating income to grow ahead of sales at a mid to high-single digit rate.

FDA Advisory Committee Unanimously Recommends Approval of Novartis's AIN457 (Secukinumab) for Patients with Moderate-To-Severe Plaque Psoriasis

Novartis announced the Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) to the US Food and Drug Administration (FDA) voted 7 to 0 to support the approval of AIN457 (secukinumab), a selective interleukin-17A (IL-17A) inhibitor, for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy (a drug that is absorbed into the bloodstream and distributed to all parts of the body) or phototherapy (light therapy). The DODAC based its recommendation on the safety and efficacy outcomes from 10 psoriasis Phase II/III clinical studies which included nearly 4,000 patients with moderate-to-severe plaque psoriasis.

Novartis Announces CTL019 Data Published in NEJM Demonstrating Efficacy in Certain Patients with Acute Lymphoblastic Leukemia

Novartis and the University of Pennsylvania’s Perelman School of Medicine (Penn) announced preliminary results from two pilot clinical trials published in The New England Journal of Medicine (NEJM) evaluating the efficacy and safety of CTL019 in patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL). The studies, conducted by Penn, demonstrated that 27 of 30 pediatric and adult patients, or 90%, experienced complete remissions with the investigational chimeric antigen receptor (CAR) therapy CTL019. These data build on earlier research findings and are part of two pilot clinical studies that demonstrated sustained remissions of up to two years in pediatric and adult patients with r/r ALL. Median follow-up was just over six months, with event-free survival of 67% and overall survival of 78%. Probability of six-month CTL019 persistence was 68% and CTL019-modified T cells were detectable in the blood by flow cytometry for up to 11 months. Sustained remissions were seen in 15 patients and were associated with CAR T cell persistence and B cell aplasia. Updated results have been submitted for presentation at a medical congress taking place later in 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVSN:MM $1,239.56 MXN 0.00

NVSN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Gilead Sciences Inc $114.22 USD +3.50
Johnson & Johnson $107.04 USD +1.48
Pfizer Inc $29.84 USD +0.35
Roche Holding AG SFr.285.40 CHF +2.00
Procter & Gamble Co/The $86.94 USD +0.40
View Industry Companies
 

Industry Analysis

NVSN

Industry Average

Valuation NVSN Industry Range
Price/Earnings 22.1x
Price/Sales 3.7x
Price/Book 3.1x
Price/Cash Flow 22.9x
TEV/Sales 3.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVARTIS AG-SPONSORED ADR, please visit www.novartis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.